文献速递免疫规划传染病防控与疫情报告

在粉纹夜蛾幼虫中与鞭毛蛋白共表达的保守HA肽可保护鸡免受鼻内H7N1高致病性禽流感病毒攻击

Conserved HA-peptides expressed along with flagellin in Trichoplusia ni larvae protects chicken against intranasal H7N1 HPAIV challenge.
PubMed 文献 · Vaccine · 2019-11-14

本研究利用粉纹夜蛾幼虫作为活体生物工厂,在杆状病毒平台中表达两种与鞭毛蛋白融合的保守HA表位(NG-34和CS-17),用幼虫表达flagellin-NG34/CS17抗原的可溶性提取物免疫鸡,评估其对异源H7N1高致病性禽流感病毒攻击的保护效果。结果显示疫苗保护了免疫鸡,并阻断了经口和泄殖腔的病毒排毒,10/12免疫个体未观察到明显临床症状,保护机制正在研究中。

要点

  • flagellin-NG34/CS17疫苗保护免疫鸡抵御异源H7N1 HPAIV攻击。
  • 疫苗阻断经口和泄殖腔的病毒排毒。
  • 10/12免疫个体未观察到明显临床症状,保护机制正在研究中。

核心结论

  • flagellin-NG34/CS17疫苗保护了免疫鸡,并阻断了经口和泄殖腔的病毒排毒,10/12免疫个体未观察到明显临床症状。
  • 所赋予的保护机制正在研究中。

研究设计与样本

  • 在基于粉纹夜蛾幼虫的杆状病毒平台中生产两种与鞭毛蛋白融合的保守表位NG-34和CS-17。
  • 用表达flagellin-NG34/CS17抗原的幼虫可溶性提取物免疫鸡,并评估其对异源H7N1 HPAIV攻击的效果。

主要发现

  • flagellin-NG34/CS17疫苗保护了免疫鸡。
  • 疫苗阻断了经口和泄殖腔的病毒排毒。
  • 10/12免疫个体未观察到明显临床症状。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The immunization of poultry where H5 and H7 influenza viruses (IVs) are endemic is one of the strategies to prevent unexpected zoonoses. Our group has been focused on conserved HA-epitopes as potential vaccine candidates to obtain multivalent immune responses against distinct IV subtypes. In this study, two conserved epitopes (NG-34 and CS-17) fused to flagellin were produced in a Baculovirus platform based on Trichoplusia ni larvae as living biofactories. Soluble extracts obtained from larvae expressing "flagellin-NG34/CS17 antigen" were used to immunize chickens and the efficacy of the vaccine was evaluated against a heterologous H7N1 HPAIV challenge in chickens. The flagellin-NG34/CS17 vaccine protected the vaccinated chickens and blocked viral shedding orally and cloacally. Furthermore, no apparent clinical signs were monitored in 10/12 vaccinated individuals. The mechanism of protection conferred is under investigation.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sisteré-Oró M, Martínez-Pulgarín S, Solanes D, et al. Conserved HA-peptides expressed along with flagellin in Trichoplusia ni larvae protects chicken against intranasal H7N1 HPAIV challenge. Vaccine. 2019. PMID: 31735501. doi:10.1016/j.vaccine.2019.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。